Ambrosia launches revolutionary “Direct-to-Apple Watch” NightRider BluCon for Continuous Glucose Monitoring

SAN FRANCISCO, July 19, 2019 /PRNewswire/ — Ambrosia Systems, a fast growing medical  technology company, today announced the launch of the next version of NightRider BluCon. The new NightRider BluCon works with Apple watch to display glucose readings from the FreeStyle Libre and Libre Pro sensors on Apple watch without the phone. This will help parents of the millions of Type 1 diabetic children monitor their children’s glucose levels when the child is away. Currently, parents don’t have a way to know the current glucose levels of their Type 1 diabetic child if he or she is not carrying their phone, which most schools don’t allow. Also, it is difficult for young children to carry their phone all the time.

After the initial setup of Ambrosia’s NightRider and LinkBluCon app on the iPhone, the user can change the mode to Apple Watch on LinkBluCon’s settings screen, this will switch the NightRider connection from the iPhone to Apple Watch and will start displaying glucose readings on Apple Watch without the phone. If Apple Watch has a cellular connection, parents can install Ambrosia’s FollowBluCon app on their phone and, after setup, will be able to see glucose readings updates of their child every five minutes.

Disclaimer:

Ambrosia apps are not FDA approved and should not be used to make medical decisions.
FreeStyle Libre is a trademark of Abbott Diabetes Care Inc. Ambrosia Systems Inc. does not have any kind of relationship with Abbott Diabetic Care or Abbott Laboratories.

About Ambrosia Systems

Ambrosia Systems is a fast growing medical technology company focused on building easy to use and affordable technology solutions for patients, providers, payers and caregivers. The NightRider BluCon is currently in use in more than 100 countries with FreeStyle Libre, FreeStyle Libre 2 and FreeStyle Libre Pro sensors. To learn more, visit www.ambrosiasys.com

Media Contacts: Mia Flaherty, Ambrosia Systems Inc. mia.flaherty@ambrosiasys.com, +1-415-293-8242

View original content to download multimedia:http://www.prnewswire.com/news-releases/ambrosia-launches-revolutionary-direct-to-apple-watch-nightrider-blucon-for-continuous-glucose-monitoring-300887904.html

SOURCE Ambrosia Systems

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

11 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

14 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

14 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

14 hours ago